This report summarizes a systematic review of intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma, and identifies needs for future research. This was one of the six high priority topics within asthma identified by a National Heart, Lung, and Blood Institute Advisory Council Asthma Expert Working group. 1 The objectives of the systematic review are:
• To assess efficacy of intermittent inhaled corticosteroid (ICS) therapy in different populations:
-Patients 0 to 4 years old with recurrent wheezing -Patients 5 years and older with persistent asthma (with or without long-acting beta agonist (LABA)
• To assess efficacy of adding long-acting muscarinic antagonist (LAMA) to ICS with or without LABA in:
-Patients 12 years and older with uncontrolled, persistent asthma.
Background
Scheduled, daily dosing of ICS is the preferred pharmacologic controller therapy for persistent asthma in patients of all ages. 1
Purpose of Review
To assess the efficacy of intermittent inhaled corticosteroids in different populations of patients with asthma and to assess whether adding long-acting muscarinic antagonists improves outcomes for patients with uncontrolled, persistent asthma.
Key Messages
• In children less than 5 years old with recurrent wheezing, intermittent use of inhaled corticosteroids during an upper respiratory tract infection decreases asthma exacerbations.
• In patients 12 years and older with persistent asthma:
using inhaled corticosteroids intermittently may be as effective as using them as a controller medication.
using inhaled corticosteroids and long-acting beta-agonists together as controller and quick relief therapy reduces asthma exacerbations compared to using inhaled corticosteroids alone or with longacting beta-agonists as a controller.
• In patients 12 years and older with uncontrolled, persistent asthma, adding long-acting muscarinic antagonists to:
inhaled corticosteroids reduces exacerbations and improves lung function.
inhaled corticosteroids and longacting beta-agonist controllers improves asthma control and lung function.
e Effective Health Care Program "Controller therapy" describes medications taken daily on a long-term basis to achieve and maintain control of persistent asthma. 2 Rather than being taken for immediate symptom relief, controller therapy is intended to reduce future exacerbations and the need for immediate symptom relief. In this report, controller medications are defined by the timing and indication for use rather than by mechanism of action.
"Quick relief" therapy describes medications used as needed upon onset of symptoms for acute symptom relief. Likewise, for this report, quick relief therapy is defined by the timing and indication for use rather than by mechanism of action.
Worsening control of asthma or other criteria may prompt changes in prescription therapy, such as intermittent dosing.
"Intermittent" dosing describes the use of medication that may vary in the dose, frequency, or duration of administration. Some examples of intermittent ICS dosing include initiating a temporary course of ICS or temporarily increasing the dose of ICS that is otherwise taken as controller therapy.
An extension of intermittent ICS therapy is the use of ICS and LABA as controller therapy both on a regular basis and on immediate symptom onset for quick relief therapy. 3 LAMA represents a new pharmacologic class of longacting bronchodilators that have been studied as a controller therapy for asthma. At least one LAMA has gained Food and Drug Administration (FDA) approval for the long-term maintenance treatment of asthma in patients 6 years and older. 4
The review focuses on drugs as a class, as described in Table A . 
Results
We found 56 unique studies (54 randomized controlled trials, 2 observational studies) in this review. Fifteen randomized controlled trials were specific to LAMA therapy in patients 12 years and older with persistent uncontrolled asthma. 
Discussion
This review evaluated different ICS dosing strategies and LAMA therapy in people of various ages with persistent asthma. Comparisons were class-based and thus this review does not inform the impact of specific doses on outcomes; rather, it more globally addresses classes and broad dosing strategies (i.e. intermittent dosing of ICS). Although effectiveness is an important part of decisionmaking, this report did not include harms associated with drug therapies, which should also be taken into consideration.
There is a relatively smaller amount of published evidence on intermittent ICS dosing as compared to the amount of evidence on combined ICS and LABA as quick relief and controller therapy or LAMA therapy. This lack of evidence should not be equated to lack of benefit necessarily. Given most outcomes were rated with low strength of evidence, future research could change the direction or magnitude of effect or the strength of evidence as the consistency and precision in effect estimates improve.
Conclusions
Compared to rescue SABA use, adding intermittent ICS use appears to benefit children less than 5 years old with recurrent wheezing in the setting of an RTI. In patients 12 years and older with persistent asthma, differences in intermittent ICS versus controller use of ICS were not detected, although few studies provided evidence leading to primarily low strength of evidence ratings. Using ICS and LABA combined as both a controller and quick relief therapy showed benefits over use as a controller medication alone (ICS or ICS and LABA controller). In patients 12 years and older with uncontrolled, persistent asthma, adding LAMA to ICS controller or ICS plus LABA controller compared to ICS or ICS plus LABA alone improves some outcomes. However, adding LAMA to ICS controller compared to adding LABA to ICS controller or increasing dosage of ICS controller did not improve outcomes.
